Washington Post Publisher Will Lewis Steps Down After Layoffs 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Prudential Financial Reports Higher Q4 Profit on Strong Underwriting and Investment Gains 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Instagram Outage Disrupts Thousands of U.S. Users 
SAN DIEGO, July 25, 2017 -- Cytori Therapeutics, Inc. (NASDAQ:CYTX) (the “Company”), announced today that the Compensation Committee of the Company's Board of Directors granted non-qualified stock options on July 19, 2017 to four (4) new employees (the “Optionees”) exercisable for an aggregate of up to 2,000 shares of the Company's common stock (the “Option Shares”), with a per share exercise price of $1.10, which was the closing price of Cytori’s common stock on the Nasdaq Capital Market on July 19, 2017. The stock options have a ten-year term and vest over a period of four years, with one quarter of the Option Shares vesting on the first anniversary of each Optionee’s employment commencement date with the Company, and with the remainder of the Option Shares vesting over the ensuing three years in thirty-six (36) equal, consecutive, monthly installments, in each case subject to each such Optionee’s continued employment with the Company as of the applicable vesting dates. The stock options are subject to the terms and conditions of the Company’s 2015 New Employee Incentive Plan and the stock option agreements pursuant to which the stock options have been granted.
The stock options were granted as an inducement material to the Optionees’ entering into employment with the Company in accordance with NASDAQ Listing Rule 5635(c)(4).
About Cytori Therapeutics, Inc.
Cytori is a therapeutics company developing regenerative and oncologic therapies from its proprietary cell therapy and nanoparticle platforms for a variety of medical conditions. Data from preclinical studies and clinical trials suggest that Cytori Cell Therapy™ acts principally by improving blood flow, modulating the immune system, and facilitating wound repair. As a result, Cytori Cell Therapy™ may provide benefits across multiple disease states and can be made available to the physician and patient at the point-of-care through Cytori’s proprietary technologies and products. Cytori Nanomedicine™ is developing encapsulated therapies for regenerative medicine and oncologic indications. For more information, visit www.cytori.com.
Cytori Therapeutics, Inc. Tiago Girao 1.858.458.0900 [email protected]
